We wonder why there are billing concerns and prior authorization requirements with insurance companies for genetic or genomic testing that patients truly deserve and, when appropriate, changes outcomes substantially in patient care? Why would these organizations put...
Recently, under the banner of “access”, a trade association that represents a number of biomarker testing laboratories sent a letter to two Medicare administrators expressing concerns about the administrators’ proposals for tightening coverage on precision oncology...
Recent Comments